Select Language
IL-2
IL-2 Overview
| English Name | Interleukin-2 | Approved Drugs | 2 |
| Drugs in Clinical Trials | 43 | Target Synonym | T-cell growth factor，IL2，Interleukin 2，T Cell Growth Factor，Aldesleukin，IL-2，TCGF，Involved In Regulation Of T-Cell Clonal Expansion，Interleukin-2，Lymphokine |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-2 |
| Target Synonym | T-cell growth factor，IL2，Interleukin 2，T Cell Growth Factor，Aldesleukin，IL-2，TCGF，Involved In Regulation Of T-Cell Clonal Expansion，Interleukin-2，Lymphokine |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 43 |
| Highest Development Stage | Approved |
IL-2 Product List
- Product Category
Protein (13)Kits (7)
- Product Status
Launched (18)In Research (2)
- Species
Human (12)Mouse (5)Cynomolgus (2)Rat (1)
- Tag
Fc Tag & Avi Tag (1)His Tag (4)Fc Tag (1)- (7)Tag Free (4)His Tag & Avi Tag (3)
- Conjugate
Biotin-labeled (4)Unconjugated (9)- (7)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CRS-B008 |  Human | - | Human IL-2 ELISA Kit | |||
HOT GMP-L02H14 | Human | E. coli | GMP Human IL-2 Protein |  |  |  |
HOT GMP-L02H14F002 | Human | E. coli | GMP Human IL-2 Protein (Liquid) |  | | |
HOT IL2-H5215 | Human | HEK293 | Human IL-2 Protein, Tag Free (MALS verified) |  | | |
CRS-A003 | Human | - | resDetect™ Human Interleukin-2 (IL-2) ELISA Kit (Residue Testing) | |||
FCSh-001 | Human | - | Human IL-2 Detection Kit (Flow Cytometry Bead Assay) | |||
FRT-C03 | Human | - | Human IL-2 Detection Kit (TR-FRET) | |||
GMP-L02H14GB01 | Human | E. coli | CytoPak GMP Human IL-2 Protein |  | | |
IL2-H5269 | Human | HEK293 | Human IL-2 Protein, Fc Tag (MALS verified) |  | |  |
IL2-H52H8 | Human | HEK293 | Human IL-2 Protein, His Tag |  | | |
Total: 20
- 1
- 2
IL-2 Background
Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.
IL-2 Synonyms
IL2,TCGF,lymphokine,Interleukin 2
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Adenomatous Polyposis Coli; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Neoplasms; Solid tumours | Details |
| IBI-363 | IBI-363 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| EQ-101 | EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Leukemia, Large Granular Lymphocytic; Lymphoma, T-Cell, Cutaneous | Details |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| SIM-0278 | ALM-223; SIM0278 | Phase 2 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Lupus Nephritis | Details |
| Imneskibart | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Carcinoma, Renal Cell; Melanoma; Solid tumours | Details |
| STK-012 | STK-012 | Phase 2 Clinical | Synthekine Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Neoplasms; Solid tumours | Details |
| STI-7349 | STI-7349; ILKN421H | Phase 2 Clinical | The Fourth Affiliated Hospital, Zhejiang University School Of Medcine | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Neoplasm Metastasis; Solid tumours | Details |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | Details |
| KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours | Details |
| REGN-10597 | REGN-10597 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Melanoma; Neoplasms; Solid tumours | Details |
| SAR-444336 | SAR-444336; THOR-809 | Phase 2 Clinical | Sanofi | Colitis, Microscopic; Inflammation | Details |
| COYA-301 | COYA-301 | Phase 2 Clinical | Coya Therapeutics Inc | Alzheimer Disease | Details |
| Saltikva | MDB401B | Phase 2 Clinical | Salspera LLC, Sunshine Lake Pharma | Pancreatic Neoplasms | Details |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | National Cancer Institute, St. Jude Children'S Research Hospital | Neuroblastoma | Details | |
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| ODC-IL2 | ODC-IL-2; ODC-IL2; ODC-1L2 | Phase 1 Clinical | Trutino Biosciences Inc | Neoplasms; Solid tumours | Details |
| Etakafusp alfa | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Neoplasms | Details |
| HM-16390 | HM-16390; HM16390 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| EGL-003 | EGL-003 | Phase 1 Clinical | Egle Therapeutics | Autoimmune Diseases; Dermatitis, Atopic; Neoplasms | Details |
| KYS-202003-A | KYS-202003-A; KYS202003A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Solid tumours | Details |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Breast Neoplasms; Colorectal Neoplasms | Details |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours | Details | |
| TEV-56278 | TEV-56278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Melanoma; Neoplasms; Solid tumours | Details |
| AttIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Osteosarcoma; Sarcoma; Soft Tissue Neoplasms | Details | |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hangzhou Houwu Biomedical Technology Co Ltd, Hervor Therapeutics, Tcrcure Biopharma Ltd | Solid tumours | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Alopecia Areata; Autoimmune Diseases; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic | Details |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
| CUG-252 | CUG-252 | Phase 1 Clinical | Cugene Inc | Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Propagermanium | SK-818; SK-818C | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Serocion | Japan | Hepatitis B | Sanwa Kagaku Kenkyusho Co Ltd | 1994-01-01 | Hepatitis B | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms | Details |
Product Reviews
JC2024-12-11
2People LikeThis product was ordered for the purpose of culturing immune cells; these cells were in turn used in downstream experiments to assess the efficacy and toxicity of ADCs. This product was delivered punctually and the labels were very clear. There is more than sufficient volume, and it worked seamlessly compared to products tried in the past. It is highly recommended for other users who work with immune cells.- K***s2023-05-18 0People LikeMy lab utilized this antibody as an analyte to prove/disprove binding capability to one of our proprietary antibodies. In addition to antibody screening, we also used it as a positive control to compare efficacy of in house IL2. We used it on Octet, which works with BLI technology to determine binding affinities. We appreciate the quick shipping and delivery of this product as our assays needed to be completed within a specific timeline.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland